ESR1 and breast cancer: Additionally, treatment of these ER+ cell lines with EZH2 inhibitor UNC1999 had no effect on tumorsphere formation (Fig 2B), thereby demonstrating that the HMT activity of EZH2 is not required for the maintenance of tumorspheres in some ER+ breast cancer cells.